A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
Key facts
- Who runs it
- National Vaccine and Serum Institute, China
- Where
- China8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 13,500 people, planned
- Started
- 4 Jun 2022
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- placebo
- Record updated
- 28 October 2026
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Can take part
Show the full registry criteria (34)Hide the full registry criteria
Who can take part
- non-gynecological related
- *Chinese women with a history of sexual life who are 18-45 years old at the time of enrollment and can provide legal identification
- *Axillary body temperature <37.3℃ on the day of enrollment
- The subjects themselves have the ability to understand the clinical trial and voluntarily sign the informed consent
- Subjects have the ability to read, understand, and fill out research application forms such as diary cards/contact cards, and promise to follow the research requirements participate in follow-up visits
- No previous HPV vaccination history, no commercially available HPV vaccine during the study period (about 6 years after enrollment) plan of
- The subject has a negative urine pregnancy test on the day before vaccination; Gynecology related
- *Effective contraception was taken from day 1 of last menstrual cycle to day 0 of the study, and no childbearing within 7 months after enrollment plan
- *Before the gynecological visit and within 48 hours before any subsequent visit that includes a gynecological sample collection: asexual life (including same-sex or opposite-sex anal, vaginal or genital contact), unwashed/washed vagina (Except for normal bathing outside the vagina), no vaginal drugs or preparations are used
Who cannot take part
- *3 months prior to vaccination or planned to receive any immune globulin or blood products within 7 months of enrollment
- *Received any vaccine within 14 days prior to vaccination, or received live vaccine within 28 days
- *3 days before vaccination, suffering from acute febrile illness (body temperature ≥38.5℃) or using antipyretic, analgesic and antiallergic drugs (eg: acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.)
- 1 month before vaccination or plan to receive immunosuppressive therapy within 7 months after enrollment, such as oral administration for more than 2 consecutive weeks Oral or injectable systemic corticosteroid therapy (≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent to prednisone) amount); however, topical medications (such as ointments, eye drops, inhalers, or nasal sprays) are not limited
- Previous splenectomy or impaired spleen function
- Those with previous or current severe liver, kidney and cardiovascular diseases, complicated diabetes, and malignant tumors
- Participate in other clinical studies (drugs, vaccines and medical devices) within 3 months before vaccination or during the planned study period
- *Pregnant, breastfeeding, or within 6 weeks of pregnancy at the time of the first dose of the vaccine
- Previous history of abnormal cervical cancer screening or lesions (including HPV DNA positive, squamous intraepithelial lesion (SIL)or atypical squamous cells of undetermined significance (ASC-US), atypical squamous epithelial cells - excluding high-grade squamous cells Intraepithelial lesions (ASC-H), atypical glandular cells (AGC) or with cervical intraepithelial neoplasia (CIN),Adenocarcinoma in situ (AIS) or cervical cancer, etc.)
- Previous hysterectomy or pelvic radiation therapy or severe cervical/vaginal dysplasia
- If any of the following occurs, the investigator will terminate the subject's vaccination with the investigational vaccine
- History of severe allergies/conditions requiring medical intervention (e.g. Anaphylactic shock, anaphylactic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis(Arthus reaction) etc.)
- Immunocompromised or diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia Blood disease, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammation STD or other autoimmune disease
- Have a history of epilepsy, convulsions, mental illness or a family history of mental illness
- Suffering from thrombocytopenia or any coagulation disorder that can become a contraindication to intramuscular injection
- *Acute lower genital tract infection (such as acute vulvitis/vaginitis/cervicitis, etc.) found by the naked eye during gynecological examination
- Past or current anal and genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts,vulvar cancer, vaginal cancer and anal cancer, etc.)
- First dose exclusion criteria:
- (Visits may be rescheduled if the criteria described in the "*" option are met at screening)
- Non-gynecological related
- * Those with abnormal blood pressure (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg) on physical examination before vaccination
- The investigator believes that the subject has any other factors that are not suitable for participating in the clinical trial (such as: poor compliance or planning Permanent relocation from the area before the study is completed, etc.); Gynecology related
- *The subject is in the menstrual period
- Meet the first dose exclusion criteria 5, 6, 7, 8, 9, 12
- Any other reasons that, in the judgment of the investigator, warrant discontinuation of the investigational vaccination
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.
The 2 groups in the trial
- experiment groupTreatment being tested
According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
Treatment: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- placeboPlacebo, for comparison
According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
- Record updated
- 28 October 2026